WRF
JAZZ icon

Waddell & Reed Financial’s Jazz Pharmaceuticals JAZZ Stock Holding History

Waddell & Reed Financial’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-20,000
Closed -$2.9M – 549
2017
Q1 		$2.9M Buy
+20,000
New +$2.6M 0.01% 508

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Waddell & Reed Financial's JAZZ Position: Q1 2021 in Review

Waddell & Reed Financial held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2021 at 204,901 shares worth $33.7M. The position accounts for 0.07% of the portfolio, ranked #305.

Waddell & Reed Financial first reported a position in JAZZ in Q4 2013 and has held it in 30 quarters since. The position peaked at $180M in Q1 2018. 442 funds tracked by Wall St. Rank hold JAZZ as of Q1 2021.

  • Waddell & Reed Financial held 204,901 shares of Jazz Pharmaceuticals worth $33.7M as of Q1 2021.
  • Waddell & Reed Financial left its Jazz Pharmaceuticals share count unchanged in Q1 2021.
  • Jazz Pharmaceuticals made up 0.07% of Waddell & Reed Financial's portfolio in Q1 2021, its #305 holding.
  • Waddell & Reed Financial first reported a position in Jazz Pharmaceuticals in Q4 2013 and has held it in 30 quarters since.
  • Waddell & Reed Financial's Jazz Pharmaceuticals position peaked at $180M in Q1 2018.
  • 442 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2021.

Based on Waddell & Reed Financial's 13F filing for Q1 2021, filed 12 May 2021.